Skip to main content
Mark Joseph Eliason
( out of 592 reviews )

Mark Joseph Eliason, MD

Languages spoken: English

Clinical Locations

Midvalley Health Center

Murray
801-581-2955

Sugar House Health Center

Salt Lake City
801-581-2000

University of Utah Hospital

Dermatology, Area E
Salt Lake City
801-581-2955
  • Mark Eliason, MD has specialized interest in skin cancer and inflammatory diseases of the skin. He is board certified in dermatology. He has completed a two-year fellowship in familial melanoma genetics and published research in this area. In addition, he has interest in inflammatory diseases such as urticaria and eczema. He sees patients for any general dermatologic concerns.

    Board Certification

    American Board of Dermatology (Dermatology)

    Patient Rating

    5.0 /5
    ( out of 592 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 30, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Personable, communicative and competent. Excellent qualities!

    September 30, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr Eliason is the most polite and considerate physician I have ever met. He is not only knowledgeable, but also caring and sensitive. His professionalism is balanced with a deep sense of humanity.

    September 29, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    A great doctor! Caring, thorough and professional!!

    September 28, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Eliason is fantastic, kind and gentle even when the procedures he does for my health are painful. He explains things in a great way and is up to date with current information. I trust him completely.

    September 27, 2024
    UH HOSPITALS AND CLINICS

    Dr. Eliason is simply the BEST!

    September 27, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Eliason is a caring professional who carefully explains things, is receptive to questions, and provides great care.

    September 27, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Eliason is the best! He is knowledgeable and professional as well as kind. He listens to concerns carefully and consistently comes up with effective treatment plans.

    September 25, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Eliason is at the top of the top in his profession.

    September 24, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    A great Physician.

  • Mark Eliason, MD has specialized interest in skin cancer and inflammatory diseases of the skin. He is board certified in dermatology. He has completed a two-year fellowship in familial melanoma genetics and published research in this area. In addition, he has interest in inflammatory diseases such as urticaria and eczema. He sees patients for any general dermatologic concerns.

    Board Certification and Academic Information

    Academic Departments Dermatology -Primary
    Board Certification
    American Board of Dermatology (Dermatology)

    Education history

    Residency Dermatology - University of Utah School of Medicine Resident
    Familial Melanoma - Huntsman Cancer Institute Research Fellow
    Internship Internal Medicine - University of Utah School of Medicine Intern
    Medicine - University of California - Irvine M.D.
    Undergraduate Molecular Biology - Brigham Young University B.S.

    Selected Publications

    Journal Article

    1. Carlisle RP, Flint ND, Hopkins ZH, Eliason MJ, Duffin KC, Secrest AM (2020). Administrative Burden and Costs of Prior Authorizations in a Dermatology Department. JAMA Dermatol, 156(10), 1074-1078. (Read full article)
    2. Forbes B, Secrest AM, Hand MQ, Eliason MJ (2018). Process of Post-operative Telephone Follow-up Implementation for Mohs Micrographic Surgery: A Pilot Study. J Clin Aesthet Dermatol, 11(7), 36-39. (Read full article)
    3. Clark JJ, Woodcock A, Cipriano SD, Hyde MA, Edwards SL, Frost CJ, Eliason MJ (2016). Community perceptions about the use of black salve. J Am Acad Dermatol, 74(5), 1021-3. (Read full article)
    4. Eliason MJ, Sontheimer RD (2015). How to reduce out-of-pocket costs for prescription medications.LID - 13030/qt5bk5n1vj [pii]. Dermatol Online J, 21(6). (Read full article)
    5. Eliason MJ, Leachman SA, Feng BJ, Schwartz ME, Hansen CD (2012). A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol, 67(4), 680-6. (Read full article)
    6. Pho LN, Eliason MJ, Regruto M, Hull CM, Powell DL (2011). Treatment of chronic urticaria with colchicine. J Drugs Dermatol, 10(12), 1423-8. (Read full article)
    7. Pho LN, Smith FJ, Konecki D, Bale S, McLean WH, Cohen B, Eliason MJ, Leachman SA (2011). Paternal germ cell mosaicism in autosomal dominant pachyonychia congenita. Arch Dermatol, 147(9), 1077-80. (Read full article)
    8. Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL (2011). Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. J Am Acad Dermatol, 64(6), 1221-2. (Read full article)
    9. McLean WH, Hansen CD, Eliason MJ, Smith FJ (2011). The phenotypic and molecular genetic features of pachyonychia congenita. J Invest Dermatol, 131(5), 1015-7. (Read full article)
    10. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther, 18(2), 442-6. (Read full article)
    11. Eliason MJ, Bowen GM, Bowen AR, Hazzard L, Samlowski WE (2009). Primary Treatment of Verrucous Carcinoma of the Penis with 5-fluorouracil, cis-diamino-dichloro platinum and Radiation Therapy Arch Derm). Arch Dermatol, 145(11), 1291.
    12. Larson AA, Leachman SA, Eliason MJ, Cannon-Albright LA (2007). Population-based assessment of non-melanoma cancer risk in relatives of cutaneous melanoma probands. J Invest Dermatol, 127(1), 183-8. (Read full article)
    13. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, Leachman SA (2006). Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol, 126(3), 660-6. (Read full article)

    Review

    1. Millsop JW, Heller MM, Eliason MJ, Murase JE (2013). Dermatological medication effects on male fertility. [Review]. Dermatol Ther, 26(4), 337-46. (Read full article)
    2. Leachman SA, Jackson R, Eliason MJ, Larson AA, Bolognia JL (2007). Management of melanoma during pregnancy. [Review]. Dermatol Nurs, 19(2), 145-52, 161. (Read full article)

    Case Report

    1. Eliason MJ, Hansen CB, Hart M, Porter-Gill P, Chen W, Sturm RA, Bowen G, Florell SR, Harris RM, Cannon-Albright LA, Swinyer L, Leachman SA (2007). Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation. Arch Dermatol, 143(11), 1409-12. (Read full article)

    Letter

    1. Houston NA, Secrest AM, Harris RJ, Mori WS, Eliason MJ, Phillips CM, Ferris LK (2016). Patient Preferences During Skin Cancer Screening Examination. [Letter to the editor]. JAMA Dermatol, 152(9), 1052-4. (Read full article)
    2. Clark JJ, Secrest AM, Hull CM, Eliason MJ, Leiferman KM, Gleich GJ, Powell DL (2016). The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review. [Letter to the editor]. J Am Acad Dermatol, 74(6), 1274-6. (Read full article)